US Patent Issued to Blueprint Medicines on Oct. 27 for "Treatment of eosinophilic disorders with avapritinib" (Massachusetts Inventor)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,773,409, issued on Oct. 27, was assigned to Blueprint Medicines Corp. (Cambridge, Mass.).

"Treatment of eosinophilic disorders with avapritinib" was invented by Brenton Mar (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the use of Compound (I) or a pharmaceutically acceptable salt thereof, for the treatment of an eosinophilic disorder, including hypereosinophilic syndrome."

The patent was filed on Oct. 5, 2020, under Application No. 17/766,200.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtm...